Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT06685523
Recruiting Not applicable

Evaluation of Fractalkine and Its Receptor in Peri-implantitis

NCT06685523 · tracked via the Priya Life Science Turkey tracker
Sponsor
Kubilay BARIŞ
Phase
Not applicable
Started
2024-11-08
Last updated
2024-11-12

Condition(s) studied

Peri-implantitis

Investigational drug(s) / intervention(s)

Subgingival debridementEr:YAG laser decontaminationDiyot laser decontamination

Subgingival debridement: To be applied 1 times (0. days)

Er:YAG laser decontamination: To be applied 3 times

Diyot laser decontamination: To be applied 3 times

Study summary

In this study, mechanical debridement group, Er:YAG laser group and diode laser group will be compared in terms of reducing peri-implant sulcus depth in the treatment of peri-implantitis.

Eligibility

Sex
ALL
Min age
40 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Probing depth of 4-6 mm, bone loss of at least 2 mm on X-ray and presence of inflammatory symptoms in soft tissue * No systemic disease that may affect the outcome of the treatment * Patients with healthy periodontium or patients with completed periodontal treatment * Individuals at least 6 months after prosthesis loading on the implant * Individuals who do not require further surgery for the treatment of peri-implantitis * Implants with at least 2 mm keratised gingiva * Individuals aged 40-60 years Exclusion Criteria: * Individuals undergoing radiation therapy * Individuals who smoke and drink alcohol * Individuals in pregnancy or lactation * Individuals who have received antibiotic treatment in the last three months * Individuals with parafunctional habits

Primary outcome measure(s)

  • Probing depth, clinical attachment loss — sixth month
    Measurement will be made with a periodontal probe. The unit of measurement is millimetre. The primary outcome measures are interrelated.

Trial sites (1)

FacilityCityRegionStatus
Kırıkkale University, Faculty of Dentistry, Department of Periodontology Kirikkale Turkey (Türkiye) Recruiting

Other trials for the same condition

Comparison of Dental Implants with Different Surface Properties Enrolling by invitation
Non-Surgical Treatment of Peri-Implantitis With Ultrasonic Carbon Tip Recruiting
Investigation of Macrophage Polarization in Peri-implant Health and Peri-implantitis Recruiting
Electrolytic Surface Decontamination in the Surgical Treatment of Peri-implantitis: A Randomized Clinical Trial Starting soon
Reconstructive Treatment of Peri-implantitis With Combined Defects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06685523 on ClinicalTrials.gov ↗ ← All trials in Turkey